Dr. Robinson (Sophie) is an Associate at Cure Ventures with over a decade of experience in academic research and industry, both in the United States and abroad.
Prior to joining Cure Ventures, Sophie was a doctoral candidate at the German Center of Neurodegenerative Diseases and the Institute for Stroke and Dementia Research in Munich, Germany. Her focus was centered on unraveling the complex role of microglia in frontotemporal dementia (FTD), employing cutting-edge technologies like CRISPR gene editing and induced pluripotent stem cells, along with an array of biochemistry and molecular biology techniques. She collaborated with biotechnology companies in Germany and in the US on a potential antibody treatment and investigated the link between the genetic risk and the pathology of GRN-associated FTD. Before her Ph.D., she worked in various labs at Stanford University and Yale University, making contributions to Alzheimer’s disease and cancer immunotherapy research. In addition to her academic experience, she was in clinical operations at Genentech, where she worked on streamlining study initiation in early phase clinical trials for cancer immunotherapy.
Joining Cure Ventures marks Sophie’s transition from academic research to a focus on biotech venture capital. In her current role, she aspires to integrate her extensive scientific knowledge with strategic investment insights, aiming to advance early-stage biotech innovations that have the potential to revolutionize healthcare.
Sophie received her Ph.D. in Neuroscience at the Ludwig Maximilian University of Munich in the laboratories of Dr. Christian Haass and Dr. Dominik Paquet and holds a B.S. in Psychology and Biological Sciences from Carnegie Mellon University. Her academic and research background positions her as an asset to Cure Ventures, poised to make significant contributions to the firm’s ongoing and future initiatives.